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Abstract
Introduction Osteoarthritis trials usually report average
changes in visual analogue scale (VAS) pain, and examine the
difference between treatment and placebo. We investigated
whether dichotomous responder analysis provides a more
informative interpretation of drug efficacy.
Methods Merck supplied the number of patients who, by 6
weeks, had achieved pain relief compared with a baseline of 0%
or more, 10% or more, 20% or more, and so on at equal intervals
up to 90% or more. These different levels of pain relief were
used to distinguish different definitions of responders, for
example at least 50% pain relief from baseline. Numbers and
percentages of patients achieving each level were identified.
Information was sought from a dose–response trial over 6
weeks in osteoarthritis using placebo and using etoricoxib at 5,
10, 30 and 60 mg daily.
Results With placebo, the proportions of patients achieving at
least 20%, 50% and 70% pain relief over baseline at 6 weeks
were 30%, 11% and 2%. With 60 mg etoricoxib the equivalent
percentages were 74%, 49% and 29%. The numbers needed
to treat for 30 mg and 60 mg etoricoxib to produce at least 50%
pain relief at 6 weeks compared with placebo were 4.2 (95%
confidence interval 3.8 to 8.6) and 2.6 (2.0 to 3.9), respectively.
Levels of pain relief of 50% and above discriminated best
between different doses of etoricoxib.
Conclusion Responder analysis seemed to be more sensitive
than examination of average changes in VAS pain scores.
Validation would require calculations to be performed on a set
of trials using individual patient data not available in publications.
Introduction
In recent years, meta-analyses of randomised trials in osteoar-
thritis have suggested that the benefits of some well-estab-
lished therapies – oral non-steroidal anti-inflammatory drugs
(NSAIDs), topical NSAIDs, intra-articular steroid injections,
and opioids – are small and limited to the first 2 to 3 weeks
after the start of treatment [1]. The argument is that, with 10
mm out of 100 mm average difference over placebo, the ben-
efits just reach a threshold for minimal perceptible improve-
ment, and barely achieve the threshold for a slight
improvement. Criticism of these therapies even suggests 'that
it is time to reconsider the place of these drug therapies in
OAK [osteoarthritis of the knee] management'.
This and previous papers [2] have been criticised on the basis
that average results from clinical trials do not adequately cap-
ture benefits to individuals [3,4], and that clinical trials meas-
ure what is measurable, not necessarily what is important [4].
Considerable effort has gone into looking at ways in which out-
puts in arthritis trials can be made more relevant to clinical
practice, for individuals as a therapeutic success [5], or by
efforts to incorporate priorities from subscales [6].
Whatever the eventual success of these methods, science is
informing us that there are very large differences between indi-
viduals, and that small changes in genetic makeup can greatly
influence response to drugs. We know, for instance, that there
is variation in plasma concentration and pharmacological
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response [7], and this may be responsible for some of the
large differences between patients in outcomes such as blood
pressure [8]. Similar issues affect morphine [9] and other anal-
gesics [10]. In acute pain, patients also show large differ-
ences, some having virtually no pain relief whereas others have
high levels of pain relief, but few patients are found to be aver-
age [11]. The use of average results from such highly skewed
distributions has been shown to produce unreliable results
[12]. Clinical trials in depression have investigated the individ-
ual response [13], and this has led to the assertion that 'equal
on average is not equal for everyone' [14].
We therefore sought to use data from a single clinical trial in
osteoarthritis to explore whether a more informative interpreta-
tion of osteoarthritis trials might be obtained by using dichoto-
mous responder analysis, as has been done previously for
acute [11,15] and chronic pain [16,17]. This was intended as
a pilot analysis, which, if successful, could be extended into a
more detailed examination of possible outcomes derived from
dichotomous rather than continuous scores, using larger data
sets and meta-analytic methods.
Materials and methods
To obtain a range of responses, we asked Merck Research
Laboratories (Rahway, NJ, USA) for responder information
from clinical trial 007 [18]. They provided data on placebo and
on 5, 10, 30 and 60 mg doses of etoricoxib. The trial was dou-
ble blind and randomised, and included patients with radio-
graphic and clinical diagnosis of knee osteoarthritis who were
at least 40 years old and whose symptoms had persisted for
at least 6 months.
Patients discontinued their pre-study NSAID for a period rang-
ing from 3 to 8 days (for instance diclofenac) to 10 to 15 days
(piroxicam). For inclusion, pain on a 100 mm scale had to be a
minimum 40 mm walking on a flat surface at the flare visit, plus
at least 15 mm increase and worsening in investigator global
assessment since baseline visit. This was designated the flare,
and if patients fulfilled these and other criteria they were ran-
domised to treatment with placebo (n = 60) or with etoricoxib
at single daily doses of 5 mg (n = 117), 10 mg (n = 114), 30
mg (n = 102), 60 mg (n = 112) or 90 mg (n = 112) for 6
weeks.
We asked Merck to supply the number of patients in each
group who, by 6 weeks, had achieved pain relief compared
with baseline of at least 0%, at least 10%, at least 20%, and
so on at equal points to at least 90%. The numbers and per-
centages of patients achieving, say, at least 50% pain relief
from baseline, might be defined as a responder, and presenta-
tion of data in this way allowed different definitions of
responder to be applied.
The number needed to treat (NNT) to produce each level of
response for each etoricoxib dose compared with placebo
was calculated, with 95% confidence interval (CI) [19]. Rela-
tive risk with 95% CI was calculated by using the fixed effects
model [20] and was considered to be statistically significant
when the 95% CI did not include one.
Results
Patients in the trial were predominantly female (72%) and
white (89%), were aged between 40 and 87 years, had a
median duration of arthritis of 6 years, and were mostly diag-
nosed as American Rheumatism Association class II/III (85%).
Most patients completed 6 weeks of therapy, with all-cause
discontinuation rates of 8 to 17% in different groups.
There was a very wide individual range of responses to the var-
ious treatments. With each, some patients achieved only small
amounts of pain relief, whereas others had close to complete
relief. Table 1 shows the percentage of patients in each treat-
ment group who achieved various levels of pain relief at 6
weeks compared with baseline, taking placebo or 5, 10, 30 or
60 mg etoricoxib. Data on the 90 mg dose was not made avail-
able. Figure 1 shows how the percentage of patients defined
as responders at each level of pain relief declined with increas-
ing levels of pain relief. Whereas 30% of patients achieved at
least 20% pain relief with placebo, only 11% achieved at least
50% pain relief, and only 2% achieved at least 70% pain relief.
For 60 mg etoricoxib, 74% achieved at least 20% pain relief,
49% at least 50%, and 29% at least 70%.
Using at least 50% pain relief as an arbitrary level of success
to define response, the absolute differences between placebo
and 30 and 60 mg etoricoxib daily at 6 weeks were 24% and
38% of patients, respectively. The NNTs for 30 and 60 mg
etoricoxib to produce at least 50% pain relief at 6 weeks com-
pared with placebo were 4.2 (95% CI 3.8 to 8.6) and 2.6 (2.0
to 3.9), respectively.
The absolute differences between etoricoxib and placebo
were used to calculate NNTs at each level of pain relief (Figure
2). At lower levels of pain relief there was limited discrimination
between the different doses, but at higher levels there was
greater discrimination. A level of at least 50% pain relief from
baseline at 6 weeks produced an obvious dose response.
Higher levels of pain relief resulted in higher (worse) NNTs for
5 and 10 mg etoricoxib, while the 30 and 60 mg etoricoxib
doses maintained stable and reasonably low (good) NNTs
over the range of at least 10% pain relief to at least 70% pain
relief (range of NNTs 3.5 to 6.7 for 30 mg, and 2.3 to 3.6 for
60 mg).
Discussion
The trial [18] originally reported mean differences over pla-
cebo of the same order as the Bjordal meta-analysis [1]. They
were 8 mm (5 mg), 10 mm (10 mg), 14 mm (30 mg), 22 mm
(60 mg) and 19 mm (90 mg) on a 100 mm visual analogue
scale (VAS). We have used the same information from theAvailable online http://arthritis-research.com/content/10/2/R39
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same trial in the form of a responder analysis to examine
whether such an analysis is more informative. The responder
analysis demonstrated that a larger proportion of patients
achieved higher levels of pain relief with active treatment than
with placebo (Figure 1), and that the absolute difference,
illustrated by the NNT, was large, clinically significant, and
more discriminatory at higher levels of pain relief (Figure 2).
This is not a surprise. Although fewer than half of the patients
achieved at least 50% pain relief with 60 mg etoricoxib, this
level of response is not uncommon. For instance, in migraine it
is common for oral drugs to yield 50 to 60% response rates
with the low hurdle of no pain or mild pain at 2 hours after an
attack, but this falls to 20 to 40% for pain-free at 2 hours [21].
In neuropathic pain fewer than half of patients achieve 50%
pain relief with duloxetine [17], and about half with higher
doses of pregabalin [16]. Proportions were even lower in
breakthrough pain treatment [16]. In acute pain trials in stand-
ardised pain models, commonly used drug and dose combina-
tions typically produce response rates of 40 to 60% [22], and
deeper analysis shows that patients are either responders or
not [11]. Lower response rates are seen in the treatment of
depression [13]. Genetics argues for considerable inter-indi-
vidual responses to drugs [7], leading to limited response
rates for any particular drug.
The differences between active drug and placebo were large.
For instance, the NNTs for at least 50% pain relief of 4.2 (95%
CI 3.8 to 8.6) and 2.6 (2.0 to 3.9) for 30 and 60 mg etoricoxib
in osteoarthritis compare well with those found for at least
50% pain relief in postoperative pain (range 2 to more than 6
[22]), migraine (2.6 to 5.4 [21]), and neuropathic pain (2.6 to
more than 8 [23]). For a 50% improvement in symptoms
according to the American College of Rheumatology criteria
(ACR50) after 12 months of therapy, NNTs of 4 were
recorded with adalimumab, etenercept and double-dose inflix-
imab [24]. These examples of NNTs from other painful condi-
tions have similar outcomes, if different timescales. Although
no direct comparison is possible, NNTs of 5 and below are
generally regarded as markers of effective treatment, but much
higher values are useful for some prophylactic interventions
[25].
Greater discrimination between pain therapies at higher levels
of pain relief has been shown previously for acute pain [15].
That better therapies should result in more patients with higher
levels of relief is not surprising, but individual patient analysis
has not been done for migraine or neuropathic pain to allow a
comparison to be made.
Other workers have attempted to calculate numbers needed
to treat for osteoarthritis trials. For example, NNTs of 3 to 4
were calculated for pain reduction and patient global assess-
ment after intra-articular corticosteroid, on the basis of fewer
than 200 patients [26]. The NNT to achieve improvement in
pain ranged from 4 to 16 in an analysis of acetaminophen in
osteoarthritis [27]. The results calculated in this paper by
using the Western Ontario McMaster (WOMAC) pain scale
were at least comparable.
This exploratory study is limited by size, and by examining only
one trial. Validation would require calculations to be performed
on a larger set of trials using individual patient data not availa-
ble in publications, and expanded to scales other than pain
while walking on a flat surface. Outcomes other than pain
might be considered, particularly the OMERACT-OARSI (out-
come measures in rheumatoid arthritis clinical trials of the
Osteoarthritis Research Society International) definition of
Table 1
Percentage of patients group achieving various levels of pain relief at 6 weeks compared with baseline
Percentage reduction in pain from baseline Treatment group: etoricoxib daily dose (mg)
0 (placebo) (n = 57) 5 (n = 114) 10 (n = 105) 30 (n = 102) 60 (n = 109)
>0 61 77 79 84 88
≥ 10 46 67 69 75 83
≥ 20 30 55 57 58 74
≥ 30 25 44 42 50 66
≥ 40 19 32 31 43 55
≥ 50 11 19 25 34 49
≥ 60 9 11 15 27 35
≥ 70 2 6 11 17 29
≥ 8 0 2 4 551 9
≥ 9 0 0 1 315Arthritis Research & Therapy    Vol 10 No 2    Moore et al.
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responder (defined as a patient with at least 50% improve-
ment in pain or function that was at least 20 mm on a 100 mm
VAS, or at least 20% improvement in at least two of pain, func-
tion or patient global assessment that was at least 10 mm on
a 100 mm VAS [28]).
It would also be possible to test the discriminating power of
various outcomes in larger, better-conducted trials. It is main-
tained that dichotomous outcomes have less statistical power
than continuous outcomes [29]. This has been demonstrated
for studies in which the sample size is small [30]. That may not,
however, always be so, and a well-defined dichotomous out-
come can approach or exceed the power of a continuous out-
come [31].
The question is: What makes a good definition of improvement
for a patient in a clinical trial? Any definition should embody
truth, discrimination and feasibility, and so it should be readily
translatable for use in a clinical trial, make clinical sense, be
specific to the clinical situation, have good statistical power,
and be easy to calculate and interpret [31]. It is not necessarily
true that what makes best statistical sense or utility is what is
best for describing possible outcomes for patients, including
benefits alongside risks [32].
Average differences in visual analogue pain scales between
active drugs and placebo in arthritis trials seem to understate
the efficacy of active medicines. Dichotomous responder anal-
ysis using higher levels of pain relief of at least 50% over base-
line demonstrated an efficacy equivalent to that measured in
other pain states, contradicting the idea that that it is time to
reconsider the place of drug therapies in arthritis [1].
Conclusion
Reporting of a responder analysis, called a cumulative propor-
tion of responders analysis, as well as the actual proportions
achieving certain levels of pain relief (30%, 50% and 70%,
say) may be an important addition to clinical trial reporting. It
helps to show potential benefits of higher and lower than aver-
age doses for individual patients, and possibly highlights dif-
ferent criteria for determining effective or licensed doses. This
is much more informative than average differences in VAS pain
between treatment and placebo.
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